European-wide harmonisation of regulation in medicines is more successful than previously because of political, bureaucratic and institutional changes, which have induced regulators to compromise and reach consensus. It is being driven by a convergence of the institutional interests of national...

Europeanised procedures of marketing authorisation for medicines are becoming increasingly important within EU Member States relative to national licensing systems. Since 1 January 1998 parallel national applications for drug approvals in EU Member States have disappeared and it is only possible...